The CORE-KDT study: a mixed methods protocol to establish core outcomes for refractory childhood epilepsy treated

Jennifer H Carroll1, J Helen Cross2, Mary Hickson1

  • 1Faculty of Health, University of Plymouth, Plymouth, Devon, UK.

Trials
|August 17, 2022
PubMed

Insights

This study will establish a patient-centered core outcome set for childhood epilepsy treated with ketogenic diet therapy, improving research and clinical practice relevance.

Area of Science:

  • Neurology
  • Pediatrics
  • Clinical Trials

Background:

  • Core outcome sets standardize outcome measurement in research and practice.
  • No established core outcome set exists for refractory childhood epilepsy treated with ketogenic diet therapy.
  • A patient-centered approach is crucial for relevant outcome selection.

Purpose of the Study:

  • To develop a core outcome set for refractory childhood epilepsy managed with ketogenic diet therapy.
  • To ensure outcomes measured are relevant to patients, clinicians, and researchers.
  • To enhance the quality and consistency of research and clinical practice.

Main Methods:

  • A four-phase mixed-methods study.
  • Systematic scoping review of existing literature.
  • Qualitative interviews with parents and carers.
  • Two-round Delphi study with stakeholders.
  • Face-to-face consensus meeting for ratification.

Main Results:

  • A comprehensive list of outcomes will be identified and refined.
  • Stakeholder consensus will be reached on essential outcomes.
  • A validated core outcome set will be established.

Conclusions:

  • The developed core outcome set will guide future research and clinical practice.
  • It will improve outcome measurement consistency in childhood epilepsy treated with ketogenic diet therapy.
  • This will enhance the relevance and quality of studies and audits.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
261
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
134
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
491
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
260
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
565
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K